Filing Overview
Form 8-K filed by Tivic Health Systems, Inc. (Nasdaq: TIVC), although the request metadata identifies Valion Bio, Inc. The report covers events occurring on May 21–24, 2024, and was signed May 30, 2024. The company is an emerging growth company.
Material Agreement and Financial Impact
- On May 21, 2024, the company entered into an agreement with Czarnowski Display Service, Inc. to terminate its sublease for approximately 9,091 square feet of office space in Hayward, California.
- The termination became effective May 24, 2024, after receipt of the master landlord’s consent, with the sublease ending May 31, 2024. The original sublease was scheduled to expire October 31, 2025.
- The company agreed to make a one-time termination payment of $44,480.44.
- The company is also responsible for broker commissions and landlord review fees related to the new sublease arranged by CDS. The filing does not provide a clear value for these additional costs.
- Management expects the termination to reduce lease expense by approximately $200,000 over the following year and a half.
- As of the termination date, the company will have no further interest in the premises and is considering options for a new principal place of business.
Changes Versus Prior Arrangement
The company is exiting its existing office sublease approximately 17 months before its scheduled expiration. This creates an immediate termination obligation but is expected to lower future occupancy costs. The filing does not provide broader revenue, profit, cash flow, margin, debt, or liquidity metrics.
Outlook, Risks, and Unusual Items
- The expected lease-expense reduction is forward-looking and may differ from actual results.
- The company has not disclosed the timing, location, terms, or cost of replacement premises.
- Additional broker and landlord-related fees remain payable, but their amounts are not specified.
- The company cautions that actual results may differ materially from forward-looking statements because of business, operating, financial, and other risks.
Investor Verification Items
- Verify the identity of the registrant, because the filing names Tivic Health Systems, Inc., while the request metadata names Valion Bio, Inc.
- Review Exhibit 10.1 for the complete termination terms and any conditions or additional liabilities.
- Confirm the final amount and accounting treatment of the termination payment and other related fees.
- Monitor the company’s selection and cost of a replacement principal place of business.
- Assess whether the projected approximately $200,000 lease-expense reduction is reflected in subsequent financial statements.